| 名稱 | Xevinapant |
| 描述 | Xevinapant (Debio-1143) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1. |
| 細胞實驗 | Cells are seeded in 96-well flat bottom cell culture plates at a density of (3-4) × 103 cells/well with AT-406 and incubated for 4 days. The rate of cell growth inhibition after treatment with different concentrations of AT-406 is determined by assaying with (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8). WST-8 is added to each well to a final concentration of 10%, and then the plates are incubated at 37 °C for 2−3 hours. The absorbance of the samples is measured at 450 nm using a TECAN ULTRA reader. Concentration of AT-406 that inhibited cell growth by 50% (IC50) is calculated by comparing absorbance in the untreated cells and the cells treated with AT-406. (Only for Reference) |
| 激酶實驗 | Fluorescence Polarization Based Assays for XIAP, cIAP1, and cIAP2 BIR3 Proteins: FL-AT-406 (the fluorescently tagged AT-406) is employed to develop a set of new FP assays for determination of the binding affinities of Smac mimetics to XIAP, cIAP-1, and cIAP-2 BIR3 proteins. The Kd value of FL-AT-406 to each IAP protein is determined by titration experiments using a fixed concentration of FL-AT-406 and different concentrations of the protein up to full saturation. Fluorescence polarization values are measured using an Infinite M-1000 plate reader in Microfluor 2 96-well, black, round-bottom plates. To each well, FL-AT-406 (2, 1, and 1 nM for experiments with XIAP BIR3, cIAP-1 BIR3, and cIAP-2 BIR3, respectively) and different concentrations of the protein are added to a final volume of 125 μL in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 μg/mL bovine γ-globulin, 0.02% sodium azide, with 4% DMSO). Plates are mixed and incubated at room temperature for 2-3 hours with gentle shaking. The polarization values in millipolarization units (mP) are measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) are then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software. In competitive binding experiments for XIAP3 BIR3, AT-406 is incubated with 20 nM XIAP BIR3 protein and 2 nM FL-AT-406 in the assay buffer (100 mM potassium phosphate, pH 7.5; 100 μg/mL bovine γ-globulin; 0.02% sodium azide). In competitive binding experiments for cIAP1 BIR3 protein, 3 nM protein and 1 nM FL-AT-406 are used. In competitive binding experiments for cIAP2 BIR3, 5 nM protein and 1 nM FL-AT-406 are used. For each competitive binding experiment, polarization values are measured after 2-3 hours of incubation using an Infinite M-1000 plate reader.The IC50 value, the inhibitor concentration at which 50% of the bound tracer is displaced, is determined from the plot using nonlinear least-squares analysis. Curve fitting is performed using the PRISM software. A Ki value for AT-406 is calculated. |
| 體外活性 | Xevinapant是一種Smac模擬物，能夠在氫鍵和疏水作用上密切模仿AVPI肽與XIAP的結(jié)合，并與XIAP的W323有額外的疏水接觸。相比Smac AVPI肽，Xevinapant對這些IAPs的敏感性更高，綁定親和力提高了50-100倍。當濃度為1μM時，Xevinapant能完全恢復由500nM XIAP BIR3在無細胞系統(tǒng)中抑制的caspase-9活性。在MDA-MB-231細胞中，Xevinapant快速誘導cIAP1降解，并且能夠拉下XIAP蛋白。Xevinapant對多種人類癌細胞系具有有效的抑制作用，在MDA-MB-231細胞和SK-OV-3卵巢細胞中表現(xiàn)出144和142nM的IC50，對正常類人乳腺上皮MCF-12F細胞和初級人正常前列腺上皮細胞具有低毒性。Xevinapant通過誘導caspase-3激活和PARP切割，在MDA-MB-231細胞中誘導凋亡。[1] |
| 體內(nèi)活性 | Xevinapant在小鼠、大鼠、非人類靈長類動物和狗中具有良好的藥代動力學(PK)特性和口服生物利用度。在MDA-MB-231異種移植模型中，Xevinapant有效促進cIAP1降解和procaspase-8的處理，以及在100 mg/kg劑量下腫瘤組織中PARP的裂解，并且即使在200 mg/kg的劑量下也表現(xiàn)出良好的耐受性。Xevinapant在100 mg/kg劑量下顯著抑制腫瘤生長，p值為0.0012。[1] |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 20 mg/mL (35.61 mM)
Ethanol : 93 mg/mL (165.6 mM)
|
| 關(guān)鍵字 | AT 406 | SM 406 | oral | inhibit | Debio 1143 | ovarian | IAP | degradation | Smac | Xevinapant | ARRY 334543 | Inhibitor | cancer | SM406 | AT-406 | mimetic | Debio1143 | ARRY334543 |
| 相關(guān)產(chǎn)品 | LCL161 | MX69 | Acacetin | Birinapant | 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one | ASTX660 | BV6 | N-Deshydroxyethyl Dasatinib | Se-Methylselenocysteine | AZD5582 TFA | GDC-0152 | HM90822 |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 銅死亡化合物庫 | 抗癌臨床化合物庫 | PPI抑制劑庫 | 抗癌藥物庫 |